China Jo-Jo Drugstores 10-Q 14 Nov 16 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2016	Nov. 11, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA JO-JO DRUGSTORES, INC.
Entity Central Index Key	1,413,263
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		20,374,678

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
CURRENT ASSETS
Cash	$ 8,352,091	$ 6,671,873
Financial assets available for sale		465,165
Restricted cash	6,949,808	13,747,990
Notes receivable	169,850	15,506
Trade accounts receivable, net	10,070,611	8,054,597
Inventories	13,767,234	10,802,691
Other receivables, net	1,738,864	1,376,468
Advances to suppliers, net	3,644,598	4,230,665
Other current assets	1,733,945	1,518,048
Total current assets	46,427,001	46,883,003
PROPERTY AND EQUIPMENT, net	4,986,110	5,543,076
OTHER ASSETS
Long-term investment	179,904	108,539
Farmland assets	1,546,112	1,562,205
Long term deposits	2,370,850	2,452,056
Other noncurrent assets	2,859,998	2,595,129
Intangible assets, net	2,818,340	2,928,779
Total other assets	9,775,204	9,646,708
Total assets	61,188,315	62,072,787
CURRENT LIABILITIES
Short-term loan payable	29,984	31,011
Accounts payable, trade	21,208,208	16,667,396
Notes payable	11,674,166	17,595,634
Other payable	1,756,456	1,917,821
Other payable - related parties	2,271,790	2,199,775
Customer deposits	2,678,671	2,610,151
Taxes payable	164,904	483,770
Accrued liabilities	592,881	615,056
Total current liabilities	40,377,060	42,120,614
Warrant liability	578,156	636,301
Total liabilities	40,955,216	42,756,915
STOCKHOLDERS' EQUITY
Common stock; $0.001 par value; 250,000,000 shares authorized; 19,425,678 and 17,735,504 shares issued and outstanding as of September 30, 2016 and March 31, 2016	19,426	17,736
Additional paid-in capital	23,416,150	22,088,267
Statutory reserves	1,309,109	1,309,109
Accumulated deficit	(7,396,547)	(6,957,053)
Accumulated other comprehensive income	2,884,961	2,857,813
Total stockholders' equity	20,233,099	19,315,872
Total liabilities and stockholders' equity	$ 61,188,315	$ 62,072,787

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2016	Mar. 31, 2016
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	19,425,678	17,735,504
Common stock, shares outstanding	19,425,678	17,735,504

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
REVENUES, NET	$ 20,160,835	$ 22,577,626	$ 41,096,750	$ 43,888,918
COST OF GOODS SOLD	15,807,828	18,600,619	32,261,939	35,536,228
GROSS PROFIT	4,353,007	3,977,007	8,834,811	8,352,690
SELLING EXPENSES	3,023,322	3,418,755	5,706,043	6,515,124
GENERAL AND ADMINISTRATIVE EXPENSES	1,382,650	839,842	3,301,132	1,760,072
TOTAL OPERATING EXPENSES	4,405,972	4,258,597	9,007,175	8,275,196
(LOSS) INCOME FROM OPERATIONS	(52,965)	(281,590)	(172,364)	77,494
INTEREST INCOME	61,035	115,740	285,457	190,737
INTEREST EXPENSE	(430)	5,925	(869)	(154,006)
OTHER INCOME, NET	17,425	145,597	104,624	107,082
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	90,289	200,903	58,093	158,066
INCOMEBEFORE INCOME TAXES	115,354	113,113	274,941	305,911
PROVISION FOR INCOME TAXES (BENEFIT)	17,484	(38,062)	49,518	44,125
NET INCOME	97,870	151,175	229,023	261,786
OTHER COMPREHENSIVE (LOSS) INCOME
Foreign currency translation adjustments	(87,721)	(860,853)	27,148	(774,553)
COMPREHENSIVE (LOSS) INCOME	$ (10,149)	$ (709,678)	$ 256.171	$ (512,767)
WEIGHTED AVERAGE NUMBER OF SHARES:
Basic	19,375,773	16,537,461	18,239,065	16,096,406
Diluted	19,375,773	16,588,559	18,239,065	16,147,505
EARNINGS PER SHARES:
Basic	$ 0.01	$ 0.01	$ 0.01	$ 0.02
Diluted	$ 0.01	$ 0.01	$ 0.01	$ 0.02

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 229,023	$ 261,786
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	466,570	763,839
Stock-based compensation	1,329,574	208,450
Bad debt provision	(177,274)	(1,540,695)
Change in fair value of purchase option derivative liability	(58,145)	(158,066)
Change in operating assets:
Accounts receivable, trade	(2,190,470)	716,075
Notes receivable	(156,527)	98,698
Inventories	(3,358,110)	(1,371,177)
Other receivables	(176,334)	(556,942)
Advances to suppliers	275,098	748,185
Other current assets	(269,040)	615,329
Other noncurrent assets	(354,594)
Change in operating liabilities:
Accounts payable, trade	5,147,686	2,924,110
Other payables and accrued liabilities	(102,920)	1,133,850
Customer deposits	156,632	(2,460,559)
Taxes payable	(306,109)	116,924
Net cash provided by operating activities	455,060	1,499,807
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(49,298)	(106,200)
Decrease in Financial assets available for sale	454,608	1,293,600
Investment in a joint venture	(75,768)	(113,190)
Additions to leasehold improvements	(26,262)
Net cash provided by investing activities	303,280	1,074,210
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term bank loan		23,580
Repayment of short-term bank loan		(31,665)
Change in restricted cash	6,411,257	(4,279,182)
Repayments of notes payable	(17,196,298)	(15,589,077)
Proceeds from notes payable	11,800,003	17,407,506
Proceeds from other payables-related parties	95,088	69,977
Proceeds from equity financing		2,699,500
Net cash provided by financing activities	1,110,050	300,639
EFFECT OF EXCHANGE RATE ON CASH	(188,172)	(188,652)
INCREASE IN CASH	1,680,218	2,686,004
CASH, beginning of period	6,671,873	4,023,581
CASH, end of period	8,352,091	6,709,585
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	869	158,415
Cash paid for income taxes	42,437	35,943
Non-cash financing activities:
Issuance of stock purchase options to an investor		1,231,067
Issuance of stock purchase options to an investment bank		$ 147,728

Description of Business and Org

Description of Business and Organization	6 Months Ended
	Sep. 30, 2016
Description of Business and Organization [Abstract]
DESCRIPTION OF BUSINESS AND ORGANIZATION	Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), was incorporated in Nevada on December 19, 2006, originally under the name “Kerrisdale Mining Corporation”. On September 24, 2009, the Company changed its name to “China Jo-Jo Drugstores, Inc.” in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”), Zhejiang Shouantang Medical Technology Co., Ltd. (“Shouantang Technology”) and Hangzhou Jiutong Medical Technology Co., Ltd (“Jiutong Medical”), its wholly-owned subsidiaries. The Company is a retail, both online and offline, and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China (“China” or the “PRC”). The Company’s offline retail business is comprised primarily of pharmacies, a majority of which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”), a company that the Company controls through contractual arrangements. The Company’s offline retail business also includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (“Jiuzhou Clinic”) and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (“Jiuzhou Service”), both of which are also controlled by the Company through contractual arrangements. On December 18, 2013, Jiuzhou Service established, and held 51% of, Hangzhou Shouantang Health Management Co., Ltd. (“Shouantang Health”), a PRC company licensed to sell health care products. Shouantang Health was closed in April 2015. In May 2016, Shouantang Bio set up and held 49% of Kahamadi Bio, a joint venture specialized in brand name development for nutritional supplements. The Company’s online pharmacy license remains with Jiuzhou Pharmacy and its online retail pharmacy business was primarily conducted through Zhejiang Quannuo Internet Technology Co., Ltd. (“Quannuo Technology”), which provided technical, sales and logistic support. In May 2015, the Company established Zhejiang Jianshun Network Technology Co. Ltd, a joint venture with Shanghai Jianbao Technology Co., Ltd. (“Jianshun Network”), in order to develop its online pharmaceutical sales from large commercial medical insurance companies. On September 10, 2015, Renovation set up a new entity named Hangzhou JiuYi Medical Technology Co. Ltd. (“Jiuyi Technology”) to provide additional technical support such as webpage development to our online pharmacy business. In November 2015, the Company sold all of the equity interests of Quannou Technology to six individuals for approximately $17,121 (RMB107,074). After the sale, its technical support function has been transferred back to Jiuzhou Pharmacy, which hosts our online pharmacy. The Company’s wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. The Company’s herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”), a wholly-owned subsidiary of Jiuxin Management, which operates a cultivation project of herbal plants used for traditional Chinese medicine (“TCM”). The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation HK ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $4.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Shouantang Bio ● Established in the PRC in October 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jianshun Network ● Established in the PRC in May 2015 ● 35% held by Jiuzhou Pharmacy ● Manages sales on official website of the online pharmacy Joint Venture 35% owned by Jiuzhou Pharmacy Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements Joint Venture 49% owned by Shouantang Bio (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2016 filed with the SEC on June 28, 2016. Operating results for the three and six months ended September 30, 2016 may not be necessarily indicative of the results to be expected for the full year. The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company has adopted ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company's derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2016, the fair values of our derivative instruments that were carried at fair value (See Note 17). Active Market Observable Unobservable Total Cash and cash equivalents 8,352,091 - - 8,352,091 Notes payable - 11,674,166 - 11,674,166 Warrants liability - 471,186 - 471,186 Total 8,352,091 12,145,352 - 20,497,443 Revenue recognition Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise such as prescription and OTC drugs are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows return of certain merchandises without reasons within seven days after customer’s receipts of merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Restricted cash The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend. In the Company’s online pharmacy business, accounts receivables primarily consist of amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms. To purchase pharmaceutical products from the e-commerce platforms such as Tmall, customers are required to pay to certain non-bank third party payment instruments such as Alipay, which, in turn, will reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Advances to suppliers Advances to suppliers consist of prepayments to our vendors such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only makes purchase on certain non-medical products such as sundry. As a result, almost all of advance to suppliers balances are with Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from and payments to our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues such as discontinuing of inventory supply that have been identified. If we are having difficulty receiving products from a vendor, we take the following steps: cease purchasing products from the vendor, ask for return of our prepayment promptly, and if necessary, take legal actions. If all of these steps are unsuccessful, management then determines whether or not the prepayments should be reserved or written off. Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their costs, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use right 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the six months ended September 30, 2016 (See Note 6 and 9). Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed self-assessment and the Company’s liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2016 and March 31, 2016, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2015 and 2016, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities and the major one is the China Tax Authority. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2016 and 2015. Stock based compensation The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $113,638 and $134,887 for three months ended September 30, 2016 and 2015, respectively, and $182,487 and $198,053 for the six months ended September 30, 2016 and 2015, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancelable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 8 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2016 and March 31, 2016 were translated at 1 RMB to 0.1499 USD and at 1 RMB to 0.1551 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2016 and 2015 were at 1 RMB to 0.1515USD and at 1 RMB to 0.1617 USD, respectively. Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 74,960) per bank. As of September 30, 2016 and March 31, 2016, the Company had deposits totaling $14,962,487 and $19,956,275 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 74,960) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2016, one largest vendor accounted for 30.7% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the three months ended September 30, 2015, two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of the Company’s total advances to suppliers. For the six months ended September 30, 2016, two largest vendors accounted for 38.6% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the six months ended September 30, 2015, two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of the Company’s total advances to suppliers. For the three months and six months ended September 30, 2016 and September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. Recent Accounting Pronouncements Measurement of Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” This ASU introduces a new forward-looking approach, based on expected losses, to estimate credit losses on certain types of financial instruments, including trade receivables. The estimate of expected credit losses will require considerations of historical information, current information and reasonable and supportable forecasts. This ASU also expands the disclosure requirements to enable users of financial statements to understand the assumptions, models and methods for estimating expected credit losses. This ASU is effective for the Company beginning in the first quarter of 2020 and allows for early adoption beginning in the first quarter of 2019. The Company is currently evaluating the impact the ASU will have on its Consolidated Financial Statements. Improvements to Employee Share-Based Payment Accounting In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” requiring the recognition of the income tax effects of stock awards in the income statement when the awards are settled and allowing the Company to repurchase more of an employee's shares than allowed under current guidance, without triggering liability accounting. This ASU also addresses simplifications related to statement of cash flows classification and accounting for forfeitures. This ASU is effective for the Company beginning in the first quarter of 2017 and allows for early adoption. The Company is currently evaluating the impact this ASU will have on its Consolidated Financial Statements. Revenue Recognition In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” replacing most existing revenue recognition guidance under GAAP and eliminating industry specific guidance. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” deferring the effective date by one year. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Gross versus Net),” clarifying the principal versus agent guidance in the new revenue recognition standard, by revising the indicators to focus on evidence that the company is a principal. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” reducing the complexity when applying the guidance for identifying performance obligations and clarifying how to determine whether revenue rel

Financial Assets Available for

Financial Assets Available for Sale	6 Months Ended
	Sep. 30, 2016
Financial Assets Available For Sale [Abstract]
FINANCIAL ASSETS AVAILABLE FOR SALE	NOTE 3 – FINANCIAL ASSETS AVAILABLE FOR SALE As of September 30, 2016 and March 31, 2016, financial assets available for sale amounted to $0 and $465,165 (RMB 3,000,000), respectively. On March 28, 2016, the Company purchased from Bank of Hangzhou a wealth-management product called “Lehui 2016”, which bears an annual interest rate of 4.15% and is due and paid back on September 26, 2016. The total principal is $465,165 (RMB 3,000,000) interest received is approximately $9,433.

Trade Accounts Receivable

Trade Accounts Receivable	6 Months Ended
	Sep. 30, 2016
Trade Accounts Receivable [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 4 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: September 30, March 31, Accounts receivable $ 11,718,911 $ 10,153,840 Less: allowance for doubtful accounts (1,648,300 ) (2,099,243 ) Trade accounts receivable, net $ 10,070,611 $ 8,054,597 For the three months ended September 30, 2016 and 2015, $30,790 and $31,541 in accounts receivable were directly written off respectively. For the six months ended September 30, 2016 and 2015, $63,382 and $91,873 in accounts receivable were directly written off respectively.

Other Current Assets

Other Current Assets	6 Months Ended
	Sep. 30, 2016
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	Note 5 – OTHER CURRENT ASSETS Other current assets consisted of the following: September 30, March 31, Prepaid rental expenses(1) $ 1,316,503 $ 1,052,196 Prepaid and other current assets 417,442 465,852 Total $ 1,733,945 $ 1,518,048 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2016
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 6 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: September 30, March 31, Building $ 1,607,452 $ 1,662,510 Leasehold improvements 11,926,559 12,308,190 Farmland development cost 1,792,952 1,854,364 Office equipment and furniture 5,423,723 5,560,171 Motor vehicles 604,643 624,235 Total 21,355,329 22,009,470 Less: Accumulated depreciation (14,118,895 ) (14,138,992 ) Impairment* (2,250,324 ) (2,327,402 ) Property and equipment, net $ 4,986,110 $ 5,543,076 *The variance of impairment from March 31, 2016 to September 30, 2016 is solely caused by exchange rate variance. Total depreciation expense for property and equipment was $213,969 and $336,225 for the three months ended September 30, 2016 and 2015, respectively, and $452,979 and $748,018 for the six months ended September 30, 2016 and 2015, respectively. There were no fixed assets impaired in the three and six months ended September 30, 2016.

Advances to Suppliers

Advances to Suppliers	6 Months Ended
	Sep. 30, 2016
Advances to Suppliers [Abstract]
ADVANCES TO SUPPLIERS	Note 7 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases. Most of the Company’s vendors require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchase on a timely basis. This amount is refundable and bears no interest. As of September 30, 2016 and March 31, 2016, advance to suppliers consist of the following: September 30, March 31, Advance to suppliers $ 3,920,439 $ 4,336,207 Less: allowance for doubtful accounts (275,841 ) (105,542 ) Advance to suppliers, net $ 3,644,598 $ 4,230,665 For the three and six months ended September 30, 2016 and 2015, none of the advances to suppliers were written off against previous allowance for doubtful accounts, respectively.

Inventory

Inventory	6 Months Ended
	Sep. 30, 2016
Inventory [Abstract]
INVENTORY	Note 8 – INVENTORY Inventory consisted of finished goods, which were $13,767,234 and $10,802,691 as of September 30, 2016 and March 31, 2016, respectively. As the sales in the first two fiscal quarters were affected by G20 summit in Hangzhou, the Company planned to implement sales campaign in the third quarter and prepared more inventory. On the other hand, because suppliers usually provide higher discount and rebate rate if more inventory were purchased in bulk, the Company tends to purchase more inventory to maximize its profit margin. However, the Company constantly monitors its potential obsolete products and is allowed to return products close to expiration dates to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately. As a result, no reserves were made as of September 30, 2016 and March 31, 2016.

Farmland Assets

Farmland Assets	6 Months Ended
	Sep. 30, 2016
Farmland Assets [Abstract]
FARMLAND ASSETS	Note 9 – FARMLAND ASSETS Farmland assets are ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of September 30, 2016 and March 31, 2016, farmland assets consisted of the following: September 30, March 31, 2016 2016 Farmland assets $ 2,304,152 $ 2,346,209 Less: Impairment* (758,040 ) (784,004 ) Farmland assets, net $ 1,546,112 $ 1,562,205 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2016 and March 31, 2016.

Long Term Deposits, Landlords

Long Term Deposits, Landlords	6 Months Ended
	Sep. 30, 2016
Long Term Deposits, Landlords [Abstract]
LONG TERM DEPOSITS, LANDLORDS	Note 10 – LONG TERM DEPOSITS, LANDLORDS As of September 30, 2016 and March 31, 2016, long term deposits amounted to $2,370,850 and $2,452,056, respectively. Long term deposits are money deposited with or advanced to landlords for securing retail store leases for which the Company does not anticipate applying or being returned within the next twelve months. Most of the Company’s landlords require a minimum of nine months’ rent being paid upfront plus additional deposits.

Other Noncurrent Assets

Other Noncurrent Assets	6 Months Ended
	Sep. 30, 2016
Other Noncurrent Assets [Abstract]
OTHER NONCURRENT ASSETS	Note 11 – OTHER NONCURRENT ASSETS September 30, March 31, 2016 2016 Prepayment for headquarter office(1) $ 350,813 $ - Prepayment for lease of land use right(2) 2,509,185 2,595,129 Other noncurrent assets $ 2,859,998 $ 2,595,129 (1) As of September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020. As of September 30, 2016, prepaid rental for less than one year was classified as current assets, the remaining balance of $350,813 was classified as noncurrent assets. (2) The prepayment for lease of land use right is a payment made to a local government in connection with entering into a 30-year operating land lease agreement. The land is currently used to cultivate Ginkgo trees. This prepayment includes a deposit of $1,049,440, which will be refundable on the due date. Based on expected output from planted Gingko trees such as expected fruit production and tree market value, the fair value of the lease prepayment was lower than carrying cost. As a result, the Company recorded impairment on the lease prepayment. The amortization of the prepayment for the lease of land use right was approximately $15,484 and $17,438 for the three months ended September 30, 2016 and 2015, respectively. The amortization of the prepayment for the lease of land use right was approximately $31,289 and $33,387 for the six months ended September 30, 2016 and 2015, respectively. The Company’s amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: Years ending September 30, Amount 2017 $ 62,578 2018 62,578 2019 62,578 2020 62,578 2021 62,578 Thereafter 1,146,855

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2016
Intangible Assets [Abstract]
INTANGIBLE ASSETS	Note 12– INTANGIBLE ASSETS Net intangible assets consisted of the following at: September 30, March 31, License (1) $ 1,440,732 $ 1,482,492 Land use rights (2) 1,461,951 1,512,027 Total intangible assets 2,902,683 2,994,519 Less: accumulated amortization (84,343 ) (65,740 ) Intangible assets, net $ 2,818,340 $ 2,928,779 Amortization expense of intangibles amounted to $6,101 and $7,808 for the three months ended September 30, 2016 and 2015, respectively, and $13,591 and $15,821for the six months ended September 30, 2016 and 2015, respectively. (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by insurance cards at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City. (2) In July 2013, the Company purchased the land use right of a plot of farmland in Lin’ an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in near future.

Notes Payable

Notes Payable	6 Months Ended
	Sep. 30, 2016
Notes Payable [Abstract]
NOTES PAYABLE	Note 13 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank (“HUB”), Bank of Hangzhou (“BOH”), Industrial and Commercial Bank of China (“ICBC”) and Zhejiang Tailong Commercial Bank (“ZTCB”) that provided working capital in the form of the following bank acceptance notes at September 30, 2016 and March 31, 2016: Origination Maturity September 30, March 31, Beneficiary Endorser date date 2016 2016 Jiuzhou Pharmacy(1) HUB 04/22/15 04/21/16 - 1,550,550 Jiuzhou Pharmacy(1) HUB 04/29/15 04/28/16 - 3,333,683 Jiuzhou Pharmacy(1) HUB 10/09/15 04/09/16 - 1,708,706 Jiuzhou Pharmacy(1) HUB 11/02/15 05/02/16 - 2,553,756 Jiuzhou Pharmacy(2) BOH 12/27/15 05/27/16 - 1,592,415 Jiuzhou Pharmacy(1) HUB 12/28/15 06/28/16 - 2,741,372 Jiuzhou Pharmacy(2) BOH 12/29/15 06/29/16 - 58,913 Jiuzhou Pharmacy(3) ICBC 02/03/16 08/03/16 - 1,307,114 Jiuzhou Pharmacy(1) HUB 03/07/16 09/07/16 - 2,749,125 Jiuzhou Pharmacy(1) HUB 04/05/16 10/05/16 1,280,317 - Jiuzhou Pharmacy(1) HUB 05/06/16 11/06/16 1,601,737 - Jiuzhou Pharmacy(2) BOH 06/06/16 12/06/16 2,128,394 - Jiuzhou Pharmacy(4) ZTCB 06/24/16 12/24/16 599,680 - Jiuzhou Pharmacy(2) BOH 06/27/16 12/27/16 749,600 - Jiuzhou Pharmacy(1) HUB 06/29/16 12/29/16 1,247,334 - Jiuzhou Pharmacy(1) HUB 08/05/16 02/05/17 1,462,141 - Jiuzhou Pharmacy(1) HUB 08/29/16 02/28/17 2,604,963 - Total $ 11,674,166 $ 17,595,634 (1) As of March 31, 2016, the Company had $14,696,105 (RMB94,779,950) of notes payable from HUB. The Company is required to hold restricted cash of $11,278,693 (RMB72,739,950) with HUB as collateral against these bank notes. As of September 30, 2016, the Company had $8,196,492 (RMB 54,672,441) of notes payable from HUB. The Company is required to hold restricted cash of $2,561,032 (RMB17,082,660) with HUB as collateral against these bank notes. (2) As of March 31, 2016, the Company had $1,592,415 (RMB10,270,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $480,671 (RMB3,100,000) with BOH as collateral against these bank notes. As of September 30, 2016, the Company had $2,877,994 (RMB 19,196,865) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,738,837 (RMB 11,598,432) with BOH as collateral against these bank notes. (3) As of March 31, 2016, the Company had $1,307,114 (RMB8,430,000) of notes payable from ICBC, with restricted cash of $928,051 (RMB5,985,300) held at the bank. As of September 30, 2016, the Company had no notes payable from ICBC. (4) As of September 30, 2016, the Company had $599,680 (RMB4,000,000) of notes payable from ZTCB, with restricted cash of $299,840 (RMB2,000,000) held at the bank. As of September 30, 2016, the Company had a credit line of approximately $14.02 million in the aggregate from HUB, BOH, ICBC and ZTCB. By putting up the restricted cash of $4.30 million deposited in the banks, the total credit line was $18.32 million. As of September 30, 2016, the Company had approximately $11.67 million of bank notes payable and approximately $6.65 million bank credit line was still available for further borrowing. The bank notes are also secured by buildings owned by the Company’s major shareholders, land use rights of Jiutong Medical, a shop of Jiuzhou Pharmacy, and guaranteed by Jiuxin Medical.

Taxes

Taxes	6 Months Ended
	Sep. 30, 2016
Taxes [Abstract]
TAXES	Note 14 – TAXES Income tax For the three and six months ended September 30, 2016 and 2015, the income tax provisions were as follow: Three months ended Six months ended 2016 2015 2016 2015 Income tax $ 17,484 $ (38,062 ) $ 45,918 $ 44,125 The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC The following table reconciles the U.S. statutory tax rates with the Company's effective tax rate for the three and six months ended September 30, 2016 and 2015: For the three months For the six months ended September 30, ended September 30, 2016 2015 2016 2015 U.S. Statutory rates 34 .0 % 34 .0 % 34.0 % 34.0 % Foreign income not recognized in the U.S. (34.0 ) (34.0 ) (34.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (25.0 ) (25.0 ) (25.0 ) (25.0 ) Non-deductible expenses-permanent difference (2) 15.2 (5.8 ) 16.7 (27.9 ) Effective tax rate 15.2 % (5.8 )% 16.7 % (27.9 )% (1) It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The (61.8)% and 5.8% rate adjustments for the three months ended September 30, 2016 and 2015, and the (6.3)% and (27.9)% rate adjustments for the six months ended September 30, 2016 and 2015 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax. Jo-Jo Drugstores is incorporated in the U.S. and incurred a net operating loss for income tax purposes for the three and six months ended September 30, 2016 and 2015. As of September 30, 2016, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $1,503,000 which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized by 2032. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at September 30, 2015. There was no net change in the valuation allowance for the three and six months ended September 30, 2016 and 2015. Management reviews this valuation allowance periodically and makes adjustments as necessary. Taxes payable at September 30, 2016 and March 31, 2016 consisted of the following: September 30, March 31, VAT $ 134,058 $ 422,804 Income tax 15,418 10,880 Others 15,531 50,086 Total taxes payable $ 164,904 $ 483,770 The Company has adopted ASC Topic 740-10-05, “Income Taxes.” To date, the adoption of this interpretation has not impacted the Company’s financial position, results of operations, or cash flows. The Company performed self-assessment and the Company’s liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30 and March 31, 2016, management considered that the Company had no uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months and six months ended September 30, 2016 and 2015, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities and the major one is the China Tax Authority.

Postretirement Benefits

Postretirement Benefits	6 Months Ended
	Sep. 30, 2016
Postretirement Benefits [Abstract]
POSTRETIREMENT BENEFITS	Note 15 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee’s current compensation as required by the local government. The Company contributed $222,732 and $245,394 in employment benefits and pension for the three months ended September 30, 2016 and 2015, respectively, and $470,632 and $468,405 in employment benefits and pension for the six months ended September 30, 2016 and 2015, respectively.

Related Party Transactions and

Related Party Transactions and Arrangements	6 Months Ended
	Sep. 30, 2016
Related Party Transactions and Arrangements [Abstract]
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	Note 16 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: September 30, March 31, Due to cofounders (1): $ 576,818 $ 576,818 Due to a director and CEO (2): 1,694,972 1,622,957 Total $ 2,271,790 $ 2,199,775 (1) As of September 30, 2016 and March 31, 2016, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements. (2) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. As of September 30, 2016 and March 31, 2016, notes payable totaling $4,943,875 and $5,302,881 were secured by the personal properties of certain of the Company’s shareholders, respectively. The Company leases from Mr. Lei Liu a retail space which expires in September 2016. Rent expense amounted to $4,499 and $23,940 for the three months ended September 30, 2016 and 2015, respectively. Rent expense amounted to $9,092 and $48,510 for the six months ended September 30, 2016 and 2015, respectively. The amounts were not paid to Mr. Liu as of September 30, 2016.

Warrants

Warrants	6 Months Ended
	Sep. 30, 2016
Warrants [Abstract]
WARRANTS	Note 17 – WARRANTS On September 26, 2013, as annual compensation for its financial advisory service, the Company issued a warrant to a financial consulting firm to purchase up to 150,000 shares of common stock at $1.20 per share. The warrant is exercisable from September 26, 2013 to September 25, 2016. On September 21, 2016, the warrants were exercised at the stock price of $1.84. As a result, 52,174 shares were issued. On September 26, 2013, the issuance date of the warrant, the Company classified its fair value as a liability of $33,606. The Company recognized a gain of $93,606 and $200,903 from the change in fair value of the warrant liability for the three months ended September 30, 2016 and September 30, 2015, The Company recognized a loss of $76,633 and $58,318 from the change in fair value of the warrant liability for the three months ended September 30, 2016 and September 30, 2015,respectively. As a result, the warrant liability is carried on the consolidated balance sheets at the fair value of $0 and $89,997 as of September 30, 2016 and March 31, 2016, respectively. In connection with the registered direct offering closed on July 19, 2015, the Company issued to an investor warrant to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The options are exercisable commencing on January 19, 2016 and will expire on January 18, 2021. In connection with the offering, the Company also issued warrants to its placement agent of this offering, which can purchase an aggregate of up to 6% of the aggregate number of shares of common stock sold in the offering, i.e. 72,000 shares. These warrants have the same terms as the warrants issued to purchaser in the offering. The fair value of the warrants issued to purchase 672,000 shares in the above was estimated by using the binominal pricing model with the following assumptions: Common Stock Common Stock September 30, March 31, Stock price $ 1.78 $ 1.60 Exercise price $ 3.10 $ 3.10 Annual dividend yield 0 % 0 % Expected term (years) 4.30 4.80 Risk-free interest rate 1.14 % 1.21 % Expected volatility 99.39 % 102.16 % (1) As of September 30, 2016, the warrants had not been exercised. Upon evaluation, the warrants meet the definition of a derivative under ASC 815 as the Company cannot avoid net cash settlement under certain circumstances. Accordingly, the fair value of the warrants was classified as a liability of $546,304 as of March 31, 2016. For the three and six months ended September 30, 2016, the Company recognized a loss of $3,265 and $18,488 for the investor warrants and placement agent warrants, from the change in fair value of the warrants liability. As a result, the warrants liability is carried on the consolidated balance sheets at the fair value of $578,156 for the investor warrants and placement agent warrants, as of September 30, 2016.

Stockholder's Equity

Stockholder's Equity	6 Months Ended
	Sep. 30, 2016
Stockholder's Equity [Abstract]
STOCKHOLDER'S EQUITY	Note 18 – STOCKHOLDER’S EQUITY Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. Share-based awards are attributed to expense using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under ASC 718 “Compensation - Stock Compensation.” The assumptions used in calculating the fair value of share-based payment awards represent the Company’s best estimates. The Company’s estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. On November 25, 2015, the Company agreed to grant a total of 150,000 shares of restricted common stock to a financial consulting firm for its financial advisory services. The term of the service agreement is one year. The trading value of the Company’s common stock on November 25, 2015 was $1.77. For the three and six months ended September 30, 2016, $66,921 and $133,114 was recorded as a consulting expense. On November 27, 2015, the Company granted a total of 735,000 shares of restricted common stock to its directors, officers and certain employees under the Company’s 2010 Equity Incentive Plan, as amended (the “Plan”). The stock awards vests in one year. The trading value of the Company’s common stock on November 27, 2015 was $1.76. For the three and six months ended September 30, 2016, 326,058 and $648,572 was recorded as service compensation expense. On June 7, 2016, the Company granted a total of 8,000 shares of restricted common stock to Taylor Raffery, an investor relation firm, for its marketing services. The trading value of the Company’s common stock in June 2016 was $1.60. Taylor Raffery’s service ended in June 2016. As a result, for the three and six months ended September 30, 2016, $0 and $12,800 was recorded as a consulting expense. On June 3, 2016, the Company granted a total of 1,630,000 shares of restricted common stock to its key employees in retail drugstores and online pharmacy under the Company’s 2010 Equity Incentive Plan, as amended. The stock awards vests in three year. The trading value of the Company’s common stock on June 3, 2016 was $1.62. For the three and six months ended September 30, 2016, $221,859 and $286,970 was recorded as service compensation expense. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests in three years on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the three months ended September 30, 2016 and 2015, $124,033 and $124,033 was recorded as compensation expense. For the six months ended September 30, 2016 and 2015, $248,066 and $248,066 was recorded as compensation expense. As of September 30, 2016, there was approximately $0.56 million of total unrecognized compensation costs related to stock option compensation arrangements granted which is expected to be recognized over the remaining weighted-average period of 1.13 years. Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividend or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three and six months ended September 30, 2016 and 2015, the Company did not make appropriations to the statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.

Income Per Share

Income Per Share	6 Months Ended
	Sep. 30, 2016
Income Per Share [Abstract]
INCOME PER SHARE	Note 19 – INCOME PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted earnings per share computation: Three months ended Six months ended 2016 2015 2016 2015 Net income attributable to controlling interest $ 97,870 $ 151,175 $ 229,023 $ 261,786 Weighted average shares used in basic computation 19,375,773 16,537,461 18,239,065 16,096,406 Diluted effect of purchase options and warrants - 51,099 - 51,099 Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 19,375,773 16,588,560 18,239,065 16,147,505 Income per share – Basic: Net income before noncontrolling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Loss per share – Diluted: Net income before noncontrolling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Add: Net income attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 For the three and six months ended September 30, 2016, the 967,000 shares underlying employee stocks options and 600,000 shares underlying outstanding purchase options to an investor, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive. For the three and months ended September 30, 2015, no warrants were excluded from the calculation of diluted earnings per share as the options were anti-dilutive.

Segments

Segments	6 Months Ended
	Sep. 30, 2016
Segments [Abstract]
SEGMENTS	Note 19 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter (“OTC”) medicines, TCM, dietary supplements, medical devices, and sundry items to retail customers. The online pharmacy sells OTC drugs, dietary supplements, medical devices and sundry items to customers through several third-party platforms such as Alibaba’s Tmall, JD.com and Amazon.com, and the Company’s own platform all over China. The drug wholesale segment includes supplying the Company’s own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company’s herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments' accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company's reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operation for the three months ended September 30, 2016: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 12,806,987 $ 3,783,725 $ 3,570,123 $ - $ 20,160,835 Cost of goods 9,037,377 3,386,588 3,383,863 - 15,807,828 Gross profit $ 3,769,610 $ 397,137 $ 186,260 $ - $ 4,353,007 Selling expenses 2,192,969 450,866 379,487 - 3,023,322 General and administrative expenses 1,652,375 - (276,910 )* 7,185 ) 1,382,650 (Loss) income from operations $ (75,734 ) $ (53,729 ) $ 83,683 $ (7,185 ) $ (52,965 ) Depreciation and amortization $ 466,051 $ - $ 6,644 $ - $ 472,695 Total capital expenditures $ 40,084 $ - $ - $ - $ 40,084 * includes the accounts receivable and advance to suppliers allowance reversal of $318,789. The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2015: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 13,103,135 $ 6,558,407 $ 2,916,084 $ - $ 22,577,626 Cost of goods 10,177,989 5,737,312 2,685,318 - 18,600,619 Gross profit $ 2,925,146 $ 821,095 $ 230,766 $ - $ 3,977,007 Selling expenses 3,230,986 51,462 136,307 - 3,418,755 General and administrative expenses 1,191,832 214,315 (47,827 )* (518,478 ) 839,842 (Loss) income from operations $ (1,497,672 ) $ 555,318 $ 142,286 $ 518,478 ) $ (281,590 ) Depreciation and amortization $ 134,720 $ - $ 130,103 $ 79,209 $ 344,032 Total capital expenditures $ 6,200 $ 690 $ (83 ) $ - $ 6,807 * includes the accounts receivable and advance to suppliers allowance reversal of $850,079. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2016: Retail Online Drug Herb Total Revenue $ 25,515,229 $ 8,854,804 $ 6,726,717 $ - $ 41,096,750 Cost of goods 18,124,144 7,800,678 6,337,117 - 32,261,939 Gross profit $ 7,391,085 $ 1,054,126 $ 389,600 $ - $ 8,834,811 Selling expenses 4,401,929 912,912 391,202 - 5,706,043 General and administrative expenses 3,180,948 - 108,476 11,708 3,301,132 (Loss) income from operations $ (191,792 ) $ 141,214 $ (110,078 ) $ (11,708 ) $ (172,364 ) Depreciation and amortization $ 412,859 $ - $ 53,711 $ - $ 466,570 Total capital expenditures $ 49,298 $ - $ - $ - $ 49,298 * includes the accounts receivable and advance to suppliers allowance reversal of $280,645. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2015: Retail Online Drug Herb Total Revenue $ 25,274,023 $ 12,524,175 $ 6,090,720 $ - $ 43,888,918 Cost of goods 19,215,883 10,681,595 5,638,750 - 35,536,228 Gross profit $ 6,058,140 $ 1,842,580 $ 451,970 $ - $ 8,352,690 Selling expenses 5,805,454 458,712 250,958 - 6,515,124 General and administrative expenses 2,291,554 445,930 (467,225 ) (510,187 ) 1,760,072 (Loss) income from operations $ (2,038,868 ) $ 937,938 $ 668,237 $ 510,187 $ 77,494 Depreciation and amortization $ 329,727 $ - $ 273,609 $ 160,503 $ 763,839 Total capital expenditures $ 93,132 $ 6,669 $ 6,399 $ - $ 106,200 * includes the accounts receivable and advance to suppliers allowance reversal of $1,586,818. The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company's net revenue from external customers through its retail stores by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ 4,097,127 $ 4,789,007 $ 8,368,229 $ 9,435,383 Over-the-counter drugs 5,188,201 5,436,301 10,063,556 10,332,993 Nutritional supplements 965,346 1,029,519 2,142,086 1,940,130 Traditional Chinese medicine 1,120,808 1,276,488 2,049,831 2,412,997 Sundry products 223,799 341,663 478,357 603,710 Medical devices 1,176,034 230,157 2,377,497 548,810 Total $ 12,771,315 $ 13,103,135 $ 25,479,556 $ 25,274,023 The Company’s net revenue from external customers through online pharmacy by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,309,143 1,730,043 2,946,434 3,610,327 Nutritional supplements 536,456 559,390 1,444,479 1,073,134 Traditional Chinese medicine - - - - Sundry products 405,341 2,587,169 1,071,504 3,814,123 Medical devices 1,532,784 1,681,805 3,392,386 4,026,592 Total $ 3,783,724 $ 6,558,407 $ 8,854,803 $ 12,524,175 The Company’s net revenue from external customers through wholesale by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ 1,948,879 $ 1,808,043 $ 3,846,484 $ 3,711,364 Over-the-counter drugs 1,621,129 1,077,992 2,840,030 2,274,770 Nutritional supplements 31,170 23,346 70,493 43,931 Traditional Chinese medicine 4,453 - 4,453 - Sundry products - 3,482 - 6,414 Medical devices 165 3,221 931 54,240 Total $ 3,605,796 $ 2,916,084 $ 6,762,391 $ 6,090,720

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2016
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 20 – COMMITMENTS AND CONTINGENCIES Operating lease commitments The Company recognizes lease expense on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs. The Company’s commitments for minimum rental payments under its leases for the next five years and thereafter are as follows: Periods ending September 30, Retail Online Drug Herb Total 2017 $ 2,684,661 $ 37,278 $ 74,556 $ - $ 2,796,495 2018 2,354,654 37,278 74,556 - 2,466,488 2019 1,842,029 37,278 74,556 - 1,953,863 2020 1,004,782 37,278 74,556 - 1,116,616 2021 370,069 12,426 24,852 - 407,347 Thereafter 515,510 - - - 515,510 Total rent expense amounted to $722,190 and $1,178,159 for the three months ended September 30, 2016 and 2015, respectively, and $1,477,442 and $2,427,544 for the six months ended September 30, 2016 and 2015, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 21 – SUBSEQUENT EVENTS On October 11, 2016, the Company issued a total of 949,000 shares of common stock to Lei Liu, at $1.69 per share, the fair market value, or the closing stock price on Nasdaq on October 11, 2016, to offset the debts in the amount of $1,603,810 owed to Mr. Liu.

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2016 filed with the SEC on June 28, 2016. Operating results for the three and six months ended September 30, 2016 may not be necessarily indicative of the results to be expected for the full year. The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation.
Consolidation of variable interest entities	Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
Risks and Uncertainties	Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
Use of estimates	Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
Fair value measurements	Fair value measurements The Company has adopted ASC Topic 820, “Fair Value Measurement and Disclosure,” which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 13). The carrying amount of the Company's derivative instruments is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2016, the fair values of our derivative instruments that were carried at fair value (See Note 17). Active Market Observable Unobservable Total Cash and cash equivalents 8,352,091 - - 8,352,091 Notes payable - 11,674,166 - 11,674,166 Warrants liability - 471,186 - 471,186 Total 8,352,091 12,145,352 - 20,497,443
Revenue recognition	Revenue recognition Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise such as prescription and OTC drugs are not allowed to be returned after the customers leave the counter. Return of other products, such as sundry products, are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows return of certain merchandises without reasons within seven days after customer’s receipts of merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.
Restricted cash	Restricted cash The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
Accounts receivable	Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend. In the Company’s online pharmacy business, accounts receivables primarily consist of amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms. To purchase pharmaceutical products from the e-commerce platforms such as Tmall, customers are required to pay to certain non-bank third party payment instruments such as Alipay, which, in turn, will reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
Advances to suppliers	Advances to suppliers Advances to suppliers consist of prepayments to our vendors such as pharmaceutical manufacturers and other distributors. Since the acquisition of Jiuxin Medicine, we have transferred almost all logistics services of our retail drugstores to Jiuxin Medicine. Jiuzhou Pharmacy only makes purchase on certain non-medical products such as sundry. As a result, almost all of advance to suppliers balances are with Jiuxin Medicine. Advances to suppliers for our drug wholesale business consist of prepayments to our vendors such as pharmaceutical manufacturers and other distributors. We typically receive products from vendors within three to nine months after making prepayments. We continuously monitor delivery from and payments to our vendors while maintaining a provision for estimated credit losses based upon historical experience and any specific supplier issues such as discontinuing of inventory supply that have been identified. If we are having difficulty receiving products from a vendor, we take the following steps: cease purchasing products from the vendor, ask for return of our prepayment promptly, and if necessary, take legal actions. If all of these steps are unsuccessful, management then determines whether or not the prepayments should be reserved or written off.
Inventories	Inventories Inventories are stated at the lower of cost or market value. Cost is determined using the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse location. Herbs the Company farms are recorded at their cost, which includes direct costs such as seed selection, fertilizer, labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development cost. All costs are accumulated until the time of harvest and then allocated to harvested herbs costs when the herbs are sold. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference, if any, between the cost of the inventory and its estimated realizable value.
Farmland assets	Farmland assets Herbs that the Company farms are recorded at their costs, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold.
Property and equipment	Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized.
Intangible assets	Intangible assets Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use right 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
Impairment of long lived assets	Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There were no fixed assets and farmland assets impaired for the six months ended September 30, 2016 (See Note 6 and 9).
Notes payable	Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
Income taxes	Income taxes The Company follows FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The Company has adopted FASB ASC Topic 740-10-25, which provides criteria for the recognition, measurement, presentation and disclosure of uncertain tax position. The Company must recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed self-assessment and the Company’s liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2016 and March 31, 2016, the management of the Company considered that the Company had no additional liabilities for uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in the future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months ended September 30, 2015 and 2016, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities and the major one is the China Tax Authority.
Value added tax	Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subject to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2016 and 2015.
Stock based compensation	Stock based compensation The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
Advertising and promotion costs	Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $113,638 and $134,887 for three months ended September 30, 2016 and 2015, respectively, and $182,487 and $198,053 for the six months ended September 30, 2016 and 2015, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities.
Operating leases	Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancelable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 8 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term.
Foreign currency translation	Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2016 and March 31, 2016 were translated at 1 RMB to 0.1499 USD and at 1 RMB to 0.1551 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2016 and 2015 were at 1 RMB to 0.1515USD and at 1 RMB to 0.1617 USD, respectively.
Concentrations and credit risk	Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to RMB 500,000 (USD 74,960) per bank. As of September 30, 2016 and March 31, 2016, the Company had deposits totaling $14,962,487 and $19,956,275 that were covered by such limited insurance, respectively. Any balance over RMB 500,000 (USD 74,960) per bank in PRC will not be covered. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2016, one largest vendor accounted for 30.7% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the three months ended September 30, 2015, two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of the Company’s total advances to suppliers. For the six months ended September 30, 2016, two largest vendors accounted for 38.6% of the Company’s total purchases and one vendor accounted for 9.9% of the Company’s total advances to suppliers. For the six months ended September 30, 2015, two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of the Company’s total advances to suppliers. For the three months and six months ended September 30, 2016 and September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Measurement of Credit Losses on Financial Instruments In June 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” This ASU introduces a new forward-looking approach, based on expected losses, to estimate credit losses on certain types of financial instruments, including trade receivables. The estimate of expected credit losses will require considerations of historical information, current information and reasonable and supportable forecasts. This ASU also expands the disclosure requirements to enable users of financial statements to understand the assumptions, models and methods for estimating expected credit losses. This ASU is effective for the Company beginning in the first quarter of 2020 and allows for early adoption beginning in the first quarter of 2019. The Company is currently evaluating the impact the ASU will have on its Consolidated Financial Statements. Improvements to Employee Share-Based Payment Accounting In March 2016, the FASB issued ASU 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” requiring the recognition of the income tax effects of stock awards in the income statement when the awards are settled and allowing the Company to repurchase more of an employee's shares than allowed under current guidance, without triggering liability accounting. This ASU also addresses simplifications related to statement of cash flows classification and accounting for forfeitures. This ASU is effective for the Company beginning in the first quarter of 2017 and allows for early adoption. The Company is currently evaluating the impact this ASU will have on its Consolidated Financial Statements. Revenue Recognition In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” replacing most existing revenue recognition guidance under GAAP and eliminating industry specific guidance. The core principle of the new guidance is that an entity should recognize revenue for the transfer of goods and services equal to an amount it expects to be entitled to receive for those goods and services. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” deferring the effective date by one year. In March 2016, the FASB issued ASU 2016-08, “Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Gross versus Net),” clarifying the principal versus agent guidance in the new revenue recognition standard, by revising the indicators to focus on evidence that the company is a principal. In April 2016, the FASB issued ASU 2016-10, “Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing,” reducing the complexity when applying the guidance for identifying performance obligations and clarifying how to determine whether revenue related to a performance obligation for an intellectual property license is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients,” clarifying certain core recognition principles including collectability, sales tax presentation, noncash consideration, contract modifications and completed contracts at transition. These ASUs are effective for the Company beginning in the first quarter of 2018, allow for early adoption in the first quarter of 2017 and may be applied using either a full retrospective approach or a modified retrospective approach. The Company is currently evaluating the method of adoption and the impact these ASUs will have on its Consolidated Financial Statements.

Description of Business and O29

Description of Business and Organization (Tables)	6 Months Ended
	Sep. 30, 2016
Description of Business and Organization [Abstract]
Schedule of consolidated financial statements activities	Entity Name Background Ownership Renovation HK ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $4.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Shouantang Bio ● Established in the PRC in October 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name 100% Jianshun Network ● Established in the PRC in May 2015 ● 35% held by Jiuzhou Pharmacy ● Manages sales on official website of the online pharmacy Joint Venture 35% owned by Jiuzhou Pharmacy Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation ● Technical support to online pharmacy 100% Kahamadi Bio ● Established in the PRC in May 2016 ● 49% held by Shouantang Bio ● Registered capital of RMB 10 million ● Develop brand name for nutritional supplements Joint Venture 49% owned by Shouantang Bio (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies [Abstract]
Summary of fair value of derivative instruments	Active Market Observable Unobservable Total Cash and cash equivalents 8,352,091 - - 8,352,091 Notes payable - 11,674,166 - 11,674,166 Warrants liability - 471,186 - 471,186 Total 8,352,091 12,145,352 - 20,497,443
Schedule of estimated useful lives of property and equipment	Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years
Schedule of estimated useful lives of intangible assets	Estimated Useful Life Land use right 50 years Software 3 years

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2016
Trade Accounts Receivable [Abstract]
Schedule of trade accounts receivable	September 30, March 31, Accounts receivable $ 11,718,911 $ 10,153,840 Less: allowance for doubtful accounts (1,648,300 ) (2,099,243 ) Trade accounts receivable, net $ 10,070,611 $ 8,054,597

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Sep. 30, 2016
Other Current Assets [Abstract]
Schedule of other current assets	September 30, March 31, Prepaid rental expenses(1) $ 1,316,503 $ 1,052,196 Prepaid and other current assets 417,442 465,852 Total $ 1,733,945 $ 1,518,048 (1) Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2016
Property and Equipment [Abstract]
Schedule of property and equipment	September 30, March 31, Building $ 1,607,452 $ 1,662,510 Leasehold improvements 11,926,559 12,308,190 Farmland development cost 1,792,952 1,854,364 Office equipment and furniture 5,423,723 5,560,171 Motor vehicles 604,643 624,235 Total 21,355,329 22,009,470 Less: Accumulated depreciation (14,118,895 ) (14,138,992 ) Impairment* (2,250,324 ) (2,327,402 ) Property and equipment, net $ 4,986,110 $ 5,543,076 *The variance of impairment from March 31, 2016 to September 30, 2016 is solely caused by exchange rate variance.

Advances to Suppliers (Tables)

Advances to Suppliers (Tables)	6 Months Ended
	Sep. 30, 2016
Advances to Suppliers [Abstract]
Schedule of advance to suppliers	September 30, March 31, Advance to suppliers $ 3,920,439 $ 4,336,207 Less: allowance for doubtful accounts (275,841 ) (105,542 ) Advance to suppliers, net $ 3,644,598 $ 4,230,665

Farmland Assets (Tables)

Farmland Assets (Tables)	6 Months Ended
	Sep. 30, 2016
Farmland Assets [Abstract]
Schedule of farmland assets	September 30, March 31, 2016 2016 Farmland assets $ 2,304,152 $ 2,346,209 Less: Impairment* (758,040 ) (784,004 ) Farmland assets, net $ 1,546,112 $ 1,562,205 * The estimated fair value is estimated to be lower than its investment value as of September 30, 2016 and March 31, 2016.

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	6 Months Ended
	Sep. 30, 2016
Other Noncurrent Assets [Abstract]
Schedule of other noncurrent assets	September 30, March 31, 2016 2016 Prepayment for headquarter office(1) $ 350,813 $ - Prepayment for lease of land use right(2) 2,509,185 2,595,129 Other noncurrent assets $ 2,859,998 $ 2,595,129 (1) As of September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020. As of September 30, 2016, prepaid rental for less than one year was classified as current assets, the remaining balance of $350,813 was classified as noncurrent assets. (2) The prepayment for lease of land use right is a payment made to a local government in connection with entering into a 30-year operating land lease agreement. The land is currently used to cultivate Ginkgo trees. This prepayment includes a deposit of $1,049,440, which will be refundable on the due date. Based on expected output from planted Gingko trees such as expected fruit production and tree market value, the fair value of the lease prepayment was lower than carrying cost. As a result, the Company recorded impairment on the lease prepayment.
Schedule of amortizations of the prepayment for lease of land use right	Years ending September 30, Amount 2017 $ 62,578 2018 62,578 2019 62,578 2020 62,578 2021 62,578 Thereafter 1,146,855

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2016
Intangible Assets [Abstract]
Schedule of net intangible assets	September 30, March 31, License (1) $ 1,440,732 $ 1,482,492 Land use rights (2) 1,461,951 1,512,027 Total intangible assets 2,902,683 2,994,519 Less: accumulated amortization (84,343 ) (65,740 ) Intangible assets, net $ 2,818,340 $ 2,928,779 (1) This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by insurance cards at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City. (2) In July 2013, the Company purchased the land use right of a plot of farmland in Lin’ an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’an has not grown, the Company does not expect completion of the plant in near future.

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2016
Notes Payable [Abstract]
Schedule of credit facilities with bank	Origination Maturity September 30, March 31, Beneficiary Endorser date date 2016 2016 Jiuzhou Pharmacy(1) HUB 04/22/15 04/21/16 - 1,550,550 Jiuzhou Pharmacy(1) HUB 04/29/15 04/28/16 - 3,333,683 Jiuzhou Pharmacy(1) HUB 10/09/15 04/09/16 - 1,708,706 Jiuzhou Pharmacy(1) HUB 11/02/15 05/02/16 - 2,553,756 Jiuzhou Pharmacy(2) BOH 12/27/15 05/27/16 - 1,592,415 Jiuzhou Pharmacy(1) HUB 12/28/15 06/28/16 - 2,741,372 Jiuzhou Pharmacy(2) BOH 12/29/15 06/29/16 - 58,913 Jiuzhou Pharmacy(3) ICBC 02/03/16 08/03/16 - 1,307,114 Jiuzhou Pharmacy(1) HUB 03/07/16 09/07/16 - 2,749,125 Jiuzhou Pharmacy(1) HUB 04/05/16 10/05/16 1,280,317 - Jiuzhou Pharmacy(1) HUB 05/06/16 11/06/16 1,601,737 - Jiuzhou Pharmacy(2) BOH 06/06/16 12/06/16 2,128,394 - Jiuzhou Pharmacy(4) ZTCB 06/24/16 12/24/16 599,680 - Jiuzhou Pharmacy(2) BOH 06/27/16 12/27/16 749,600 - Jiuzhou Pharmacy(1) HUB 06/29/16 12/29/16 1,247,334 - Jiuzhou Pharmacy(1) HUB 08/05/16 02/05/17 1,462,141 - Jiuzhou Pharmacy(1) HUB 08/29/16 02/28/17 2,604,963 - Total $ 11,674,166 $ 17,595,634 (1) As of March 31, 2016, the Company had $14,696,105 (RMB94,779,950) of notes payable from HUB. The Company is required to hold restricted cash of $11,278,693 (RMB72,739,950) with HUB as collateral against these bank notes. As of September 30, 2016, the Company had $8,196,492 (RMB 54,672,441) of notes payable from HUB. The Company is required to hold restricted cash of $2,561,032 (RMB17,082,660) with HUB as collateral against these bank notes. (2) As of March 31, 2016, the Company had $1,592,415 (RMB10,270,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $480,671 (RMB3,100,000) with BOH as collateral against these bank notes. As of September 30, 2016, the Company had $2,877,994 (RMB 19,196,865) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,738,837 (RMB 11,598,432) with BOH as collateral against these bank notes. (3) As of March 31, 2016, the Company had $1,307,114 (RMB8,430,000) of notes payable from ICBC, with restricted cash of $928,051 (RMB5,985,300) held at the bank. As of September 30, 2016, the Company had no notes payable from ICBC. (4) As of September 30, 2016, the Company had $599,680 (RMB4,000,000) of notes payable from ZTCB, with restricted cash of $299,840 (RMB2,000,000) held at the bank.

Taxes (Tables)

Taxes (Tables)	6 Months Ended
	Sep. 30, 2016
Taxes [Abstract]
Schedule of income tax provision	Three months ended Six months ended 2016 2015 2016 2015 Income tax $ 17,484 $ (38,062 ) $ 45,918 $ 44,125
Schedule of income arising in or derived from tax jurisdiction which each entity domiciled	Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC
Schedule of reconciliation of the U.S. statutory tax rates with company's effective tax rate	For the three months For the six months ended September 30, ended September 30, 2016 2015 2016 2015 U.S. Statutory rates 34 .0 % 34 .0 % 34.0 % 34.0 % Foreign income not recognized in the U.S. (34.0 ) (34.0 ) (34.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (25.0 ) (25.0 ) (25.0 ) (25.0 ) Non-deductible expenses-permanent difference (2) 15.2 (5.8 ) 16.7 (27.9 ) Effective tax rate 15.2 % (5.8 )% 16.7 % (27.9 )% (1) It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The (61.8)% and 5.8% rate adjustments for the three months ended September 30, 2016 and 2015, and the (6.3)% and (27.9)% rate adjustments for the six months ended September 30, 2016 and 2015 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.
Schedule of taxes payable	September 30, March 31, VAT $ 134,058 $ 422,804 Income tax 15,418 10,880 Others 15,531 50,086 Total taxes payable $ 164,904 $ 483,770

Related Party Transactions an40

Related Party Transactions and Arrangements (Tables)	6 Months Ended
	Sep. 30, 2016
Related Party Transactions and Arrangements [Abstract]
Schedule of amounts payable to related parties	September 30, March 31, Due to cofounders (1): $ 576,818 $ 576,818 Due to a director and CEO (2): 1,694,972 1,622,957 Total $ 2,271,790 $ 2,199,775 (1) As of September 30, 2016 and March 31, 2016, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements. (2) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Sep. 30, 2016
Warrants [Abstract]
Schedule of estimated fair value of warrants	Common Stock Common Stock September 30, March 31, Stock price $ 1.78 $ 1.60 Exercise price $ 3.10 $ 3.10 Annual dividend yield 0 % 0 % Expected term (years) 4.30 4.80 Risk-free interest rate 1.14 % 1.21 % Expected volatility 99.39 % 102.16 % (1) As of September 30, 2016, the warrants had not been exercised.

Income Per Share (Tables)

Income Per Share (Tables)	6 Months Ended
	Sep. 30, 2016
Income Per Share [Abstract]
Schedule of reconciliation of basic and diluted earnings per share computation	Three months ended Six months ended 2016 2015 2016 2015 Net income attributable to controlling interest $ 97,870 $ 151,175 $ 229,023 $ 261,786 Weighted average shares used in basic computation 19,375,773 16,537,461 18,239,065 16,096,406 Diluted effect of purchase options and warrants - 51,099 - 51,099 Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 19,375,773 16,588,560 18,239,065 16,147,505 Income per share – Basic: Net income before noncontrolling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Loss per share – Diluted: Net income before noncontrolling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02 Add: Net income attributable to noncontrolling interest $ - $ - $ - $ - Net income attributable to controlling interest $ 0.01 $ 0.01 $ 0.01 $ 0.02

Segments (Tables)

Segments (Tables)	6 Months Ended
	Sep. 30, 2016
Segments [Abstract]
Schedule of information by segment	The following table presents summarized information by segment of the continuing operation for the three months ended September 30, 2016: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 12,806,987 $ 3,783,725 $ 3,570,123 $ - $ 20,160,835 Cost of goods 9,037,377 3,386,588 3,383,863 - 15,807,828 Gross profit $ 3,769,610 $ 397,137 $ 186,260 $ - $ 4,353,007 Selling expenses 2,192,969 450,866 379,487 - 3,023,322 General and administrative expenses 1,652,375 - (276,910 )* 7,185 ) 1,382,650 (Loss) income from operations $ (75,734 ) $ (53,729 ) $ 83,683 $ (7,185 ) $ (52,965 ) Depreciation and amortization $ 466,051 $ - $ 6,644 $ - $ 472,695 Total capital expenditures $ 40,084 $ - $ - $ - $ 40,084 * includes the accounts receivable and advance to suppliers allowance reversal of $318,789. The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2015: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 13,103,135 $ 6,558,407 $ 2,916,084 $ - $ 22,577,626 Cost of goods 10,177,989 5,737,312 2,685,318 - 18,600,619 Gross profit $ 2,925,146 $ 821,095 $ 230,766 $ - $ 3,977,007 Selling expenses 3,230,986 51,462 136,307 - 3,418,755 General and administrative expenses 1,191,832 214,315 (47,827 )* (518,478 ) 839,842 (Loss) income from operations $ (1,497,672 ) $ 555,318 $ 142,286 $ 518,478 ) $ (281,590 ) Depreciation and amortization $ 134,720 $ - $ 130,103 $ 79,209 $ 344,032 Total capital expenditures $ 6,200 $ 690 $ (83 ) $ - $ 6,807 * includes the accounts receivable and advance to suppliers allowance reversal of $850,079. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2016: Retail Online Drug Herb Total Revenue $ 25,515,229 $ 8,854,804 $ 6,726,717 $ - $ 41,096,750 Cost of goods 18,124,144 7,800,678 6,337,117 - 32,261,939 Gross profit $ 7,391,085 $ 1,054,126 $ 389,600 $ - $ 8,834,811 Selling expenses 4,401,929 912,912 391,202 - 5,706,043 General and administrative expenses 3,180,948 - 108,476 11,708 3,301,132 (Loss) income from operations $ (191,792 ) $ 141,214 $ (110,078 ) $ (11,708 ) $ (172,364 ) Depreciation and amortization $ 412,859 $ - $ 53,711 $ - $ 466,570 Total capital expenditures $ 49,298 $ - $ - $ - $ 49,298 * includes the accounts receivable and advance to suppliers allowance reversal of $280,645. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2015: Retail Online Drug Herb Total Revenue $ 25,274,023 $ 12,524,175 $ 6,090,720 $ - $ 43,888,918 Cost of goods 19,215,883 10,681,595 5,638,750 - 35,536,228 Gross profit $ 6,058,140 $ 1,842,580 $ 451,970 $ - $ 8,352,690 Selling expenses 5,805,454 458,712 250,958 - 6,515,124 General and administrative expenses 2,291,554 445,930 (467,225 ) (510,187 ) 1,760,072 (Loss) income from operations $ (2,038,868 ) $ 937,938 $ 668,237 $ 510,187 $ 77,494 Depreciation and amortization $ 329,727 $ - $ 273,609 $ 160,503 $ 763,839 Total capital expenditures $ 93,132 $ 6,669 $ 6,399 $ - $ 106,200 * includes the accounts receivable and advance to suppliers allowance reversal of $1,586,818.
Schedule of net revenue from external customers by main products	The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company's net revenue from external customers through its retail stores by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ 4,097,127 $ 4,789,007 $ 8,368,229 $ 9,435,383 Over-the-counter drugs 5,188,201 5,436,301 10,063,556 10,332,993 Nutritional supplements 965,346 1,029,519 2,142,086 1,940,130 Traditional Chinese medicine 1,120,808 1,276,488 2,049,831 2,412,997 Sundry products 223,799 341,663 478,357 603,710 Medical devices 1,176,034 230,157 2,377,497 548,810 Total $ 12,771,315 $ 13,103,135 $ 25,479,556 $ 25,274,023 The Company’s net revenue from external customers through online pharmacy by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,309,143 1,730,043 2,946,434 3,610,327 Nutritional supplements 536,456 559,390 1,444,479 1,073,134 Traditional Chinese medicine - - - - Sundry products 405,341 2,587,169 1,071,504 3,814,123 Medical devices 1,532,784 1,681,805 3,392,386 4,026,592 Total $ 3,783,724 $ 6,558,407 $ 8,854,803 $ 12,524,175 The Company’s net revenue from external customers through wholesale by main products is as follows: Three months ended Six months ended 2016 2015 2016 2015 Prescription drugs $ 1,948,879 $ 1,808,043 $ 3,846,484 $ 3,711,364 Over-the-counter drugs 1,621,129 1,077,992 2,840,030 2,274,770 Nutritional supplements 31,170 23,346 70,493 43,931 Traditional Chinese medicine 4,453 - 4,453 - Sundry products - 3,482 - 6,414 Medical devices 165 3,221 931 54,240 Total $ 3,605,796 $ 2,916,084 $ 6,762,391 $ 6,090,720

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2016
Commitments and Contingencies [Abstract]
Schedule of company's commitments for minimum rental payments	Periods ending September 30, Retail Online Drug Herb Total 2017 $ 2,684,661 $ 37,278 $ 74,556 $ - $ 2,796,495 2018 2,354,654 37,278 74,556 - 2,466,488 2019 1,842,029 37,278 74,556 - 1,953,863 2020 1,004,782 37,278 74,556 - 1,116,616 2021 370,069 12,426 24,852 - 407,347 Thereafter 515,510 - - - 515,510

Description of Business and O45

Description of Business and Organization (Details)	6 Months Ended
	Sep. 30, 2016
Schedule of consolidated financial statements activities
Entity ownership percentage	100.00%
Renovation HK [Member]
Schedule of consolidated financial statements activities
Ownership background description	Incorporated in Hong Kong SAR on September 2, 2008
Entity ownership percentage	100.00%
Jiuxin Management [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise ("WFOE") under PRC law Registered capital of $4.5 million fully paid
Entity ownership percentage	100.00%
Shouantang Technology [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid Deemed a WFOE under PRC law Invests and finances the working capital of Quannuo Technology
Entity ownership percentage	100.00%
Qianhong Agriculture [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business
Entity ownership percentage	100.00%
Jiuzhou Pharmacy [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the "Jiuzhou Grand Pharmacy" stores in Hangzhou	[1]
Entity ownership description	VIE by contractual arrangements	[1],[2]
Jiuzhou Clinic [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Entity ownership description	VIE by contractual arrangements	[1],[2]
Jiuzhou Service [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Entity ownership description	VIE by contractual arrangements	[1],[2]
Jiuxin Medicine [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services
Entity ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiutong Medical [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation
Entity ownership percentage	100.00%
Shouantang Bio [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC in October 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name
Entity ownership percentage	100.00%
Jianshun Network [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC in May 2015 35% held by Jiuzhou Pharmacy Manages sales on official website of the online pharmacy
Entity ownership description	Joint Venture 35% owned by Jiuzhou Pharmacy
Jiuyi Technology [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC on September 10, 2015 100% held by Renovation Technical support to online pharmacy
Entity ownership description	100
Kahamadi Bio [Member]
Schedule of consolidated financial statements activities
Ownership background description	Established in the PRC in May 2016 49% held by Shouantang Bio Registered capital of RMB 10 million Develop brand name for nutritional supplements
Entity ownership description	Joint Venture 49% owned by Shouantang Bio
[1]	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy.
[2]	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as subsidiaries of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy, Jiuxin Medicine and Shouantang Bio are consolidated into the financial statements of the Company.

Description of Business and O46

Description of Business and Organization (Detail Textual)	1 Months Ended	6 Months Ended
	Sep. 17, 2009shares	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	May 31, 2016USD ($)	Nov. 30, 2015USD ($)	Nov. 30, 2015CNY (¥)	Dec. 18, 2013Clinic
Description of Business and Organization [Textual]
Entity Incorporation, Date of Incorporation		Dec. 19, 2006
Renovation HK [Member]
Description of Business and Organization [Textual]
Issuance of equity consideration (in shares) | shares	7,900,000
Percentage of capital stock in exchange transaction	100.00%
Jiuxin Management [Member]
Description of Business and Organization [Textual]
Registered capital paid		$ 4,500,000
Shouantang Technology [Member]
Description of Business and Organization [Textual]
Registered capital paid		20,000,000
Registered capital requirement reduced		11,000,000
Qianhong Agriculture [Member]
Description of Business and Organization [Textual]
Registered capital paid		10,000,000
Jiuzhou Pharmacy [Member]
Description of Business and Organization [Textual]
Registered capital paid | ¥			¥ 5,000,000
Jiuzhou Service [Member]
Description of Business and Organization [Textual]
Number of medical clinics owned | Clinic							4
Percentage of ownership held							51.00%
Registered capital paid | ¥			500,000
Jiuxin Medicine [Member]
Description of Business and Organization [Textual]
Registered capital paid | ¥			¥ 10,000,000
Jiutong Medical [Member]
Description of Business and Organization [Textual]
Registered capital paid		$ 2,600,000
Shouantang Bio [Member]
Description of Business and Organization [Textual]
Percentage of capital stock in exchange transaction		100.00%	100.00%
Registered capital paid | ¥			¥ 1,000,000
Jianshun Network [Member]
Description of Business and Organization [Textual]
Percentage of capital stock in exchange transaction		35.00%	35.00%
Jiuyi Technology [Member]
Description of Business and Organization [Textual]
Percentage of capital stock in exchange transaction		100.00%	100.00%
Quannuo Technology [Member]
Description of Business and Organization [Textual]
Issuance of equity consideration					$ 17,121	¥ 107,074
Kahamadi Bio [Member]
Description of Business and Organization [Textual]
Percentage of ownership held				49.00%
Registered capital paid				$ 10,000,000

Summary of Significant Accoun47

Summary of Significant Accounting Policies (Details)	Sep. 30, 2016USD ($)
Summary of fair value of derivative instruments
Cash and cash equivalents	$ 8,352,091
Notes payable	11,674,166
Warrants liability	471,186
Total	20,497,443
Active Market for Identical Assets (Level 1) [Member]
Summary of fair value of derivative instruments
Cash and cash equivalents	8,352,091
Notes payable
Warrants liability
Total	8,352,091
Observable Inputs (Level 2) [Member]
Summary of fair value of derivative instruments
Cash and cash equivalents
Notes payable	11,674,166
Warrants liability	471,186
Total	12,145,352
Unobservable Inputs (Level 3) [Member]
Summary of fair value of derivative instruments
Cash and cash equivalents
Notes payable
Warrants liability
Total

Summary of Significant Accoun48

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Sep. 30, 2016
Leasehold improvements [Member] | Maximum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	10 years
Leasehold improvements [Member] | Minimum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	3 years
Motor vehicles [Member] | Maximum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	5 years
Motor vehicles [Member] | Minimum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	3 years
Office equipment & furniture [Member] | Maximum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	5 years
Office equipment & furniture [Member] | Minimum [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	3 years
Buildings [Member]
Schedule of estimated useful lives of property and equipment
Estimated useful lives of property and equipment	35 years

Summary of Significant Accoun49

Summary of Significant Accounting Policies (Details 2)	6 Months Ended
	Sep. 30, 2016
Land use right [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	50 years
Software [Member]
Schedule of estimated useful lives of intangible assets
Estimated useful life of intangible assets	3 years

Summary of Significant Accoun50

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2016USD ($)VendersVendor	Sep. 30, 2015USD ($)VendersVendor	Sep. 30, 2016USD ($)Vendor	Sep. 30, 2015USD ($)Vendor	Sep. 30, 2016CNY (¥)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)
Summary of Significant Accounting Policies (Textual)
Benchmark percentage of the voting ownership interest for control and common control			50.00%
Ownership percentage			100.00%
Value added tax, percentage			17.00%
Income tax description			The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution. The Company performed self-assessment and the Company's liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years.
Advertising and promotion costs	$ 113,638	$ 134,887	$ 182,487	$ 198,053
Term of agreement for operating leases			30 years
Foreign currency translation description			The balance sheet amounts, with the exception of equity, at September 30, 2016 and March 31, 2016 were translated at 1 RMB to 0.1499 USD and at 1 RMB to 0.1551 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2016 and 2015 were at 1 RMB to 0.1515USD and at 1 RMB to 0.1617 USD, respectively.
Insurance covered by own bank							$ 74,960	¥ 500,000
Deposits	14,962,487		$ 14,962,487			$ 19,956,275
Deposits not covered by insurance	$ 74,960		$ 74,960		¥ 500,000
Total Purchases [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	30.70%	24.50%	38.60%	25.30%
Number of vendors	1	2	2	2
Total advances to suppliers [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	9.90%	18.20%	9.90%	18.20%
Number of vendors | Vendor	1	1	1	1
Total sales or accounts receivable [Member]
Summary of Significant Accounting Policies (Textual)
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%
Retail drugstore leases | Minimum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			3 years
Retail drugstore leases | Maximum [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			8 years
Wholesale warehouse lease [Member]
Summary of Significant Accounting Policies (Textual)
Term of agreement for operating leases			10 years

Financial Assets Available fo51

Financial Assets Available for Sale (Details)	Mar. 28, 2016	Sep. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2016CNY (¥)
Financial assets available for sale (Textual)
Financial assets available for sale			$ 465,165	¥ 3,000,000
Interest receivable		$ 9,433
Lehui 2016 [Member] | Bank of Hangzhou [Member]
Financial assets available for sale (Textual)
Interest rate	4.15%
Due date	Sep. 26, 2016

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Trade Accounts Receivable [Abstract]
Accounts receivable	$ 11,718,911	$ 10,153,840
Less: allowance for doubtful accounts	(1,648,300)	(2,099,243)
Trade accounts receivable, net	$ 10,070,611	$ 8,054,597

Trade Accounts Receivable (De53

Trade Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Trade Accounts Receivable (Textual)
Accounts receivable written off	$ 30,790	$ 31,541	$ 63,382	$ 91,873

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Other Current Assets [Abstract]
Prepaid rental expenses	[1]	$ 1,316,503	$ 1,052,196
Prepaid and other current assets		417,442	465,852
Total		$ 1,733,945	$ 1,518,048
[1]	Represents store and office rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Details

Property and Equipment (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Schedule of estimated useful lives of property and equipment
Total		$ 21,355,329	$ 22,009,470
Less: Accumulated depreciation		(14,118,895)	(14,138,992)
Impairment	[1]	(2,250,324)	(2,327,402)
Property and equipment, net		4,986,110	5,543,076
Building [Member]
Schedule of estimated useful lives of property and equipment
Total		1,607,452	1,662,510
Leasehold improvements [Member]
Schedule of estimated useful lives of property and equipment
Total		11,926,559	12,308,190
Farmland development cost [Member]
Schedule of estimated useful lives of property and equipment
Total		1,792,952	1,854,364
Office equipment and furniture [Member]
Schedule of estimated useful lives of property and equipment
Total		5,423,723	5,560,171
Motor vehicles [Member]
Schedule of estimated useful lives of property and equipment
Total		$ 604,643	$ 624,235
[1]	The variance of impairment from March 31, 2016 to September 30, 2016 is solely caused by exchange rate variance.

Property and Equipment (Detai56

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property and Equipment (Textual)
Total depreciation expense for property and equipment	$ 213,969	$ 336,225	$ 452,979	$ 748,018

Advances to Suppliers (Details)

Advances to Suppliers (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Advances to Suppliers [Abstract]
Advance to suppliers	$ 3,920,439	$ 4,336,207
Less: allowance for doubtful accounts	(275,841)	(105,542)
Advance to suppliers, net	$ 3,644,598	$ 4,230,665

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Inventory (Textual)
Finished goods	$ 13,767,234	$ 10,802,691

Farmland Assets (Details)

Farmland Assets (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Farmland Assets [Abstract]
Farmland assets		$ 2,304,152	$ 2,346,209
Less: Impairment	[1]	(758,040)	(784,004)
Farmland assets, net		$ 1,546,112	$ 1,562,205
[1]	The estimated fair value is estimated to be lower than its investment value as of September 30, 2016 and March 31, 2016.

Long Term Deposits, Landlords (

Long Term Deposits, Landlords (Details) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Long Term Deposits, Landlords (Textual)
Long term deposits	$ 2,370,850	$ 2,452,056

Other Noncurrent Assets (Detail

Other Noncurrent Assets (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Other Noncurrent Assets [Abstract]
Prepayment for headquarter office	[1]	$ 350,813
Prepayment for lease of land use right	[2]	2,509,185	2,595,129
Other noncurrent assets		$ 2,859,998	$ 2,595,129
[1]	As of September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020. As of September 30, 2016, prepaid rental for less than one year was classified as current assets, the remaining balance of $350,813 was classified as noncurrent assets.
[2]	The prepayment for lease of land use right is a payment made to a local government in connection with entering into a 30-year operating land lease agreement. The land is currently used to cultivate Ginkgo trees. This prepayment includes a deposit of $1,049,440, which will be refundable on the due date. Based on expected output from planted Gingko trees such as expected fruit production and tree market value, the fair value of the lease prepayment was lower than carrying cost. As a result, the Company recorded impairment on the lease prepayment.

Other Noncurrent Assets (Deta62

Other Noncurrent Assets (Details 1)	Sep. 30, 2016USD ($)
Years ending September 30,
2,017	$ 62,578
2,018	62,578
2,019	62,578
2,020	62,578
2,021	62,578
Thereafter	$ 1,146,855

Other Noncurrent Assets (Deta63

Other Noncurrent Assets (Details Textual)		3 Months Ended		6 Months Ended
		Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	Sep. 30, 2015USD ($)	Mar. 31, 2016USD ($)
Other Noncurrent Assets (Textual)
Term of agreement for operating land lease				30 years	30 years
Deposit included in prepayment		$ 1,049,440		$ 1,049,440
Amortization of prepayment for lease of land use right		15,484	$ 17,438	31,289		$ 33,387
Prepaid rent				$ 584,688,000	¥ 3,900,000
Description of prepaid rental				In September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020.	In September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020.
Prepayment for headquarter office	[1]	$ 350,813		$ 350,813
[1]	As of September 30, 2016, a total of $584,688 (RMB3,900,000) was prepaid as headquarter office rental for five years from January 1, 2016 to December 31, 2020. As of September 30, 2016, prepaid rental for less than one year was classified as current assets, the remaining balance of $350,813 was classified as noncurrent assets.

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets		$ 2,902,683	$ 2,994,519
Less: accumulated amortization		(84,343)	(65,740)
Intangible assets, net		2,818,340	2,928,779
License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[1]	1,440,732	1,482,492
Land use rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total intangible assets	[2]	$ 1,461,951	$ 1,512,027
[1]	This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by insurance cards at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City.
[2]	In July 2013, the Company purchased the land use right of a plot of farmland in Lin' an, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin'an has not grown, the Company does not expect completion of the plant in near future.

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Intangible Assets (Textual)
Amortization expense of intangibles	$ 6,101	$ 7,808	$ 13,591	$ 15,821

Notes Payable (Details)

Notes Payable (Details) - USD ($)		6 Months Ended
		Sep. 30, 2016	Mar. 31, 2016
Short-term Debt [Line Items]
Notes payable		$ 11,674,166	$ 17,595,634
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/22/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 21, 2016
Notes payable	[1]		1,550,550
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/29/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 28, 2016
Notes payable	[1]		3,333,683
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/09/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 9, 2016
Notes payable	[1]		1,708,706
Jiuzhou Pharmacy [Member] | HUB [Member] | 11/02/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	May 2, 2016
Notes payable	[1]		2,553,756
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/28/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 28, 2016
Notes payable	[1]		2,741,372
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/07/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 7, 2016
Notes payable	[1]		2,749,125
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/05/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Oct. 5, 2016
Notes payable	[1]	$ 1,280,317
Jiuzhou Pharmacy [Member] | HUB [Member] | 05/06/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Nov. 6, 2016
Notes payable	[1]	$ 1,601,737
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2016
Notes payable	[1]	$ 1,247,334
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/05/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 5, 2017
Notes payable	[1]	$ 1,462,141
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/29/16 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 28, 2017
Notes payable	[1]	$ 2,604,963
Jiuzhou Pharmacy [Member] | BOH [Member] | 12/27/15 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	May 27, 2016
Notes payable	[2]		1,592,415
Jiuzhou Pharmacy [Member] | BOH [Member] | 12/29/15 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Jun. 29, 2016
Notes payable	[2]		58,913
Jiuzhou Pharmacy [Member] | BOH [Member] | 06/06/16 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Dec. 6, 2016
Notes payable	[2]	$ 2,128,394
Jiuzhou Pharmacy [Member] | BOH [Member] | 06/27/16 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Dec. 27, 2016
Notes payable	[2]	$ 749,600
Jiuzhou Pharmacy [Member] | ICBC [Member] | 02/03/16 [Member]
Short-term Debt [Line Items]
Maturity date	[3]	Aug. 3, 2016
Notes payable	[3]		1,307,114
Jiuzhou Pharmacy [Member] | ZTCB [Member] | 06/24/16 [Member]
Short-term Debt [Line Items]
Maturity date	[4]	Dec. 24, 2016
Notes payable	[4]	$ 599,680
[1]	As of March 31, 2016, the Company had $14,696,105 (RMB94,779,950) of notes payable from HUB. The Company is required to hold restricted cash of $11,278,693 (RMB72,739,950) with HUB as collateral against these bank notes. As of September 30, 2016, the Company had $8,196,492 (RMB 54,672,441) of notes payable from HUB. The Company is required to hold restricted cash of $2,561,032 (RMB17,082,660) with HUB as collateral against these bank notes.
[2]	As of March 31, 2016, the Company had $1,592,415 (RMB10,270,000) of notes payable from BOH. The land use right of the farmland in Lin'An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $480,671 (RMB3,100,000) with BOH as collateral against these bank notes. As of September 30, 2016, the Company had $2,877,994 (RMB 19,196,865) of notes payable from BOH. The land use right of the farmland in Lin'An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,738,837 (RMB 11,598,432) with BOH as collateral against these bank notes.
[3]	As of March 31, 2016, the Company had $1,307,114 (RMB8,430,000) of notes payable from ICBC, with restricted cash of $928,051 (RMB5,985,300) held at the bank. As of September 30, 2016, the Company had no notes payable from ICBC.
[4]	As of September 30, 2016, the Company had $599,680 (RMB4,000,000) of notes payable from ZTCB, with restricted cash of $299,840 (RMB2,000,000) held at the bank.

Notes Payable (Details Textual)

Notes Payable (Details Textual)	Sep. 30, 2016USD ($)	Sep. 30, 2016CNY (¥)	Mar. 31, 2016USD ($)	Mar. 31, 2016CNY (¥)
Debt Instrument [Line Items]
Notes payable	$ 11,670,000
Restricted cash	4,300,000
Aggregate line of credit amount	14,020,000
Line of credit total	18,320,000
Bank credit line facilities available for borrowing	6,650,000
Notes Payable [Member] | ICBC [Member]
Debt Instrument [Line Items]
Notes payable			$ 1,307,114	¥ 8,430,000
Restricted cash			928,051	5,985,300
Notes Payable [Member] | HUB [Member]
Debt Instrument [Line Items]
Notes payable	8,196,492	¥ 54,672,441	14,696,105	94,779,950
Restricted cash	2,561,032	17,082,660	11,278,693	72,739,950
Notes Payable [Member] | BOH [Member]
Debt Instrument [Line Items]
Notes payable	2,877,994	19,196,865	1,592,415	10,270,000
Restricted cash	1,738,837	11,598,432	$ 480,671	¥ 3,100,000
Notes Payable [Member] | ZTCB [Member]
Debt Instrument [Line Items]
Notes payable	599,680	4,000,000
Restricted cash	$ 299,840	¥ 2,000,000

Taxes (Details)

Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Taxes [Abstract]
Income tax	$ 17,484	$ (38,062)	$ 49,518	$ 44,125

Taxes (Details 1)

Taxes (Details 1)	6 Months Ended
	Sep. 30, 2016
Jo-Jo Drugstores [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	United States
Renovation [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Hong Kong, PRC
All other entities [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Mainland, PRC

Taxes (Details 2)

Taxes (Details 2)		3 Months Ended		6 Months Ended
		Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Taxes [Abstract]
U.S. Statutory rates		34.00%	34.00%	34.00%	34.00%
Foreign income not recognized in the U.S.		(34.00%)	(34.00%)	(34.00%)	(34.00%)
China income taxes		25.00%	25.00%	25.00%	25.00%
Change in valuation allowance (1)	[1]	(25.00%)	(25.00%)	(25.00%)	(25.00%)
Non-deductible expenses-permanent difference (2)	[2]	15.20%	(5.80%)	16.70%	(27.90%)
Effective tax rate		15.20%	(5.80%)	16.70%	(27.90%)
[1]	It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers.
[2]	The (61.8)% and 5.8% rate adjustments for the three months ended September 30, 2016 and 2015, and the (6.3)% and (27.9)% rate adjustments for the six months ended September 30, 2016 and 2015 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.

Taxes (Details 3)

Taxes (Details 3) - USD ($)	Sep. 30, 2016	Mar. 31, 2016
Taxes [Abstract]
VAT	$ 134,058	$ 422,804
Income tax	15,418	10,880
Others	15,531	50,086
Total taxes payable	$ 164,904	$ 483,770

Taxes (Details Textual)

Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Taxes (Textual)
Estimated net operating loss carryforwards for U.S. income tax purposes	$ 1,503,000		$ 1,503,000
Expiration date			Mar. 31, 2032
Valuation allowance, percentage				100.00%
Effective income tax rate reconciliation, equity in earnings (losses), percent	61.80%	5.80%	6.30%	27.90%

Postretirement Benefits (Detail

Postretirement Benefits (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Postretirement Benefits [Abstract]
Employment benefits and pension contribution	$ 222,732	$ 245,394	$ 470,632	$ 468,405

Related Party Transactions an74

Related Party Transactions and Arrangements (Details) - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Related Party Transaction [Line Items]
Amounts payable to related parties, Total		$ 2,271,790	$ 2,199,775
Due to cofounders [Member]
Related Party Transaction [Line Items]
Amounts payable to related parties, Total	[1]	576,818	576,818
Due to a director and CEO [Member]
Related Party Transaction [Line Items]
Amounts payable to related parties, Total	[2]	$ 1,694,972	$ 1,622,957
[1]	As of September 30, 2016 and March 31, 2016, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements.
[2]	Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Related Party Transactions an75

Related Party Transactions and Arrangements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Related Party Transactions and Arrangements (Textual)
Notes payable, related parties	$ 4,943,875		$ 4,943,875		$ 5,302,881
Mr. Lei Liu [Member]
Related Party Transactions and Arrangements (Textual)
Lease expiration date			Sep. 30, 2016
Rent expense	$ 4,499	$ 23,940	$ 9,092	$ 48,510

Warrants (Details)

Warrants (Details) - Common Stock Warrants [Member] - $ / shares	6 Months Ended		12 Months Ended
	Sep. 30, 2016	[1]	Mar. 31, 2016
Class of Warrant or Right [Line Items]
Stock price	$ 1.78		$ 1.6
Exercise price	$ 3.1		$ 3.1
Annual dividend yield	0.00%		0.00%
Expected term (years)	4 years 3 months 18 days		4 years 9 months 18 days
Risk-free interest rate	1.14%		1.21%
Expected volatility	99.39%		102.16%
[1]	As of September 30, 2016, the warrants had not been exercised.

Warrants (Details Textual)

Warrants (Details Textual) - USD ($)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 21, 2016	Jul. 19, 2015	Sep. 26, 2013	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016
Warrants (Textual)
Fair value estimation method						Binominal pricing model
Fair value of warrant liability								$ 546,304
Purchase of warrants investors						672,000
Recognized loss on fair value of warrant liability investor				$ 3,265		$ 3,265
Recognized gain loss on fair value of warrant liability placement agent				18,488		18,488
Fair value of warrant liability investor placement agent						578,156
Warrants [Member]
Warrants (Textual)
Stock purchase price per share (in dollars per share)		$ 3.10
Fair value of warrant liability			$ 33,606			0		$ 89,997
Recognized gain on fair value of warrant liability						$ 93,606	$ 200,903
Recognized loss on fair value of warrant liability				$ 76,633	$ 58,318
Maturity date		Jan. 18, 2021
Purchase of warrants investors		600,000
Purchase of warrants underwriter		72,000
Issuance of warrants to placement agent						72,000
Percentage of stock sold in offering						6.00%
Warrants [Member] | Consulting firm [Member]
Warrants (Textual)
Stock purchase price per share (in dollars per share)	$ 1.84		$ 1.20
Number of shares of common stock	52,174		150,000
Warrants exercisable date			Sep. 25, 2016

Stockholder's Equity (Details)

Stockholder's Equity (Details)	Jun. 07, 2016$ / sharesshares	Jun. 03, 2016$ / sharesshares	Nov. 27, 2015$ / sharesshares	Nov. 25, 2015$ / sharesshares	Nov. 18, 2014Grantees$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)
Stockholders' Equity (Textual)
Reserve fund percentage								50.00%
Statutory accounts percentage								10.00%
Stock option [Member]
Stockholders' Equity (Textual)
Number of granted shares | shares					967,000
Share based compensation expense						$ 124,033	$ 124,033	$ 248,066	$ 248,066
Number of directors, officers and employees in a group | Grantees					46
Exercise price of stock option | $ / shares					$ 2.50
Vesting period of options					3 years
Period for options exercisable from the vesting date					5 years			1 year 1 month 17 days
Maturity date					Nov. 17, 2022
Unrecognized compensation costs						560,000		$ 560,000
Stock-based compensation to a financial consulting firm [Member]
Stockholders' Equity (Textual)
Number of granted shares | shares				150,000
Trading value of common stock | $ / shares				$ 1.77
Term of service agreement				1 year
Consulting expense						66,921		133,114
Stock-based compensation to its directors, officers and certain employees [Member]
Stockholders' Equity (Textual)
Number of granted shares | shares			735,000
Trading value of common stock | $ / shares			$ 1.76
Share based compensation expense						326,058		648,572
Vesting period of options			1 year
Stock-based compensation to Taylor Raffery [Member]
Stockholders' Equity (Textual)
Number of granted shares | shares	8,000
Trading value of common stock | $ / shares	$ 1.60
Consulting expense						0		12,800
Stock-based compensation to employees in retail drugstores and online pharmacy [Member]
Stockholders' Equity (Textual)
Number of granted shares | shares		1,630,000
Trading value of common stock | $ / shares		$ 1.62
Share based compensation expense						$ 221,859		$ 286,970
Vesting period of options		3 years

Income Per Share (Details)

Income Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Per Share [Abstract]
Net income attributable to controlling interest	$ 97,870	$ 151,175	$ 229,023	$ 261,786
Weighted average shares used in basic computation	19,375,773	16,537,461	18,239,065	16,096,406
Diluted effect of purchase options and warrants		51,099		51,099
Diluted effect of restricted shares
Weighted average shares used in diluted computation	19,375,773	16,588,559	18,239,065	16,147,505
Income per share - Basic:
Net income before noncontrolling interest	$ 0.01	$ 0.01	$ 0.01	$ 0.02
Add: Net loss attributable to noncontrolling interest
Net income attributable to controlling interest	0.01	0.01	0.01	0.02
Loss per share - Diluted:
Net income before noncontrolling interest	0.01	0.01	0.01	0.02
Add: Net income attributable to noncontrolling interest
Net income attributable to controlling interest	$ 0.01	$ 0.01	$ 0.01	$ 0.02

Income Per Share (Details Textu

Income Per Share (Details Textual) - Stock option [Member] - shares	3 Months Ended	6 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted earnings per share	967,000	967,000
Investment Placement Agent [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted earnings per share	72,000	72,000
Investor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted earnings per share	600,000	600,000

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2016		Sep. 30, 2015		Sep. 30, 2016	Sep. 30, 2015
Segment Reporting Information [Line Items]
Revenue	$ 20,160,835		$ 22,577,626		$ 41,096,750	$ 43,888,918
Cost of goods	15,807,828		18,600,619		32,261,939	35,536,228
Gross profit	4,353,007		3,977,007		8,834,811	8,352,690
Selling expenses	3,023,322		3,418,755		5,706,043	6,515,124
General and administrative expenses	1,382,650		839,842		3,301,132	1,760,072
(Loss)income from operations	(52,965)		(281,590)		(172,364)	77,494
Depreciation and amortization	472,695		344,032		466,570	763,839
Total capital expenditures	40,084		6,807		49,298	106,200
Retail drugstores [Member]
Segment Reporting Information [Line Items]
Revenue	12,806,987		13,103,135		25,515,229	25,274,023
Cost of goods	9,037,377		10,177,989		18,124,144	19,215,883
Gross profit	3,769,610		2,925,146		7,391,085	6,058,140
Selling expenses	2,192,969		3,230,986		4,401,929	5,805,454
General and administrative expenses	1,652,375		1,191,832		3,180,948	2,291,554
(Loss)income from operations	(75,734)		(1,497,672)		(191,792)	(2,038,868)
Depreciation and amortization	466,051		134,720		412,859	329,727
Total capital expenditures	40,084		6,200		49,298	93,132
Online pharmacy [Member]
Segment Reporting Information [Line Items]
Revenue	3,783,725		6,558,407		8,854,804	12,524,175
Cost of goods	3,386,588		5,737,312		7,800,678	10,681,595
Gross profit	397,137		821,095		1,054,126	1,842,580
Selling expenses	450,866		51,462		912,912	458,712
General and administrative expenses			214,315			445,930
(Loss)income from operations	(53,729)		555,318		141,214	937,938
Depreciation and amortization
Total capital expenditures			690			6,669
Drug Wholesale [Member]
Segment Reporting Information [Line Items]
Revenue	3,570,123		2,916,084		6,726,717	6,090,720
Cost of goods	3,383,863		2,685,318		6,337,117	5,638,750
Gross profit	186,260		230,766		389,600	451,970
Selling expenses	379,487		136,307		391,202	250,958
General and administrative expenses	(276,910)	[1]	(47,827)	[2]	108,476	(467,225)
(Loss)income from operations	83,683		142,286		(110,078)	668,237
Depreciation and amortization	6,644		130,103		53,711	273,609
Total capital expenditures			83			6,399
Herb farming [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of goods
Gross profit
Selling expenses
General and administrative expenses	7,185		(518,478)		11,708	(510,187)
(Loss)income from operations	(7,185)		518,478		(11,708)	510,187
Depreciation and amortization			79,209			160,503
Total capital expenditures
[1]	includes the accounts receivable and advance to suppliers allowance reversal of $318,789.
[2]	includes the accounts receivable and advance to suppliers allowance reversal of $850,079.

Segments (Details 1)

Segments (Details 1) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Retail drugstores [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 12,771,315	$ 13,103,135	$ 25,479,556	$ 25,274,023
Retail drugstores [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	4,097,127	4,789,007	8,368,229	9,435,383
Retail drugstores [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	5,188,201	5,436,301	10,063,556	10,332,993
Retail drugstores [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	965,346	1,029,519	2,142,086	1,940,130
Retail drugstores [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,120,808	1,276,488	2,049,831	2,412,997
Retail drugstores [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	223,799	341,663	478,357	603,710
Retail drugstores [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,176,034	230,157	2,377,497	548,810
Online pharmacy [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	3,783,724	6,558,407	8,854,803	12,524,175
Online pharmacy [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online pharmacy [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,309,143	1,730,043	2,946,434	3,610,327
Online pharmacy [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	536,456	559,390	1,444,479	1,073,134
Online pharmacy [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online pharmacy [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	405,341	2,587,169	1,071,504	3,814,123
Online pharmacy [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,532,784	1,681,805	3,392,386	4,026,592
Drug Wholesale [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	3,605,797	2,916,084	6,762,391	6,090,720
Drug Wholesale [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,948,879	1,808,043	2,916,084	3,711,364
Drug Wholesale [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,621,129	1,077,992	2,840,030	2,274,770
Drug Wholesale [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	31,170	23,346	70,493	43,931
Drug Wholesale [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	4,453		4,453
Drug Wholesale [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers		3,482		6,414
Drug Wholesale [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 165	$ 3,221	$ 931	$ 54,240

Segments (Details Textual)

Segments (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)Segment	Sep. 30, 2015USD ($)
Revenue From External Customer [Line Items]
Number of operating segments | Segment			4
Operating Segments [Member]
Revenue From External Customer [Line Items]
Accounts receivable and advance to supplier allowance reversal | $	$ 318,789	$ 850,079	$ 280,645	$ 1,586,818

Commitments and Contingencies84

Commitments and Contingencies (Details)	Sep. 30, 2016USD ($)
Commitments and Contingencies [Line Items]
2,017	$ 2,796,495
2,018	2,466,488
2,019	1,953,863
2,020	1,116,616
2,021	407,347
Thereafter	515,510
Retail drugstores [Member]
Commitments and Contingencies [Line Items]
2,017	2,684,661
2,018	2,354,654
2,019	1,842,029
2,020	1,004,782
2,021	370,069
Thereafter	515,510
Online pharmacy [Member]
Commitments and Contingencies [Line Items]
2,017	37,278
2,018	37,278
2,019	37,278
2,020	37,278
2,021	12,426
Thereafter
Drug wholesale [Member]
Commitments and Contingencies [Line Items]
2,017	74,556
2,018	74,556
2,019	74,556
2,020	74,556
2,021	24,852
Thereafter
Herb farming [Member]
Commitments and Contingencies [Line Items]
2,017
2,018
2,019
2,020
2,021
Thereafter

Commitments and Contingencies85

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Commitments and Contingencies (Textual)
Total rent expense	$ 722,190	$ 1,178,159	$ 1,477,442	$ 2,427,544

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event [Member] - Mr. Lei Liu [Member]	Oct. 11, 2016USD ($)$ / sharesshares
Subsequent Event [Line Items]
Common stock shares issued | shares	949,000
Common stock price per share | $ / shares	$ 1.69
Debt amount | $	$ 1,603,810